AbbVie Inc.
AbbVie Reports Q2 2024 Financial Results and Raises Guidance
Summary
AbbVie Inc. reported second-quarter 2024 net revenues of $14.462 billion, an increase of 4.3% on a reported basis. The company posted a GAAP diluted EPS of $0.77 and adjusted diluted EPS of $2.65, impacted by $0.52 per share from acquired IPR&D and milestones expense. AbbVie raised its full-year 2024 adjusted diluted EPS guidance range from $10.61 - $10.81 to $10.71 - $10.91. The company also announced FDA approval for Skyrizi for ulcerative colitis and submitted applications for Rinvoq for giant cell arteritis. Additionally, AbbVie completed the acquisition of Landos Biopharma and announced new collaborations.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement